These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20146342)

  • 1. Histology of highly echolucent regions in optical coherence tomography images from two patients with sirolimus-eluting stent restenosis.
    Nagai H; Ishibashi-Ueda H; Fujii K
    Catheter Cardiovasc Interv; 2010 May; 75(6):961-3. PubMed ID: 20146342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Various optical coherence tomographic findings in restenotic lesions after sirolimus-eluting stent implantation.
    Takano M; Xie Y; Murakami D; Inami S; Yamamoto M; Ohba T; Seino Y; Mizuno K
    Int J Cardiol; 2009 May; 134(2):263-5. PubMed ID: 18403032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    Matsumoto D; Shite J; Shinke T; Otake H; Tanino Y; Ogasawara D; Sawada T; Paredes OL; Hirata K; Yokoyama M
    Eur Heart J; 2007 Apr; 28(8):961-7. PubMed ID: 17135281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neointimal coverage on drug-eluting stent struts crossing side-branch vessels using optical coherence tomography.
    Her AY; Lee BK; Shim JM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Am J Cardiol; 2010 Jun; 105(11):1565-9. PubMed ID: 20494663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very late thrombosis of sirolimus-eluting stent due to late malapposition: serial observations with optical coherence tomography.
    Sawada T; Shite J; Shinke T; Tanino Y; Ogasawara D; Kawamori H; Kato H; Miyoshi N; Yoshino N; Hirata K
    J Cardiol; 2008 Dec; 52(3):290-5. PubMed ID: 19027609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents.
    Chieffo A; Foglieni C; Nodari RL; Briguori C; Sangiorgi G; Latib A; Montorfano M; Airoldi F; Michev I; Carlino M; Colombo A; Maseri A
    Am J Cardiol; 2009 Dec; 104(12):1660-7. PubMed ID: 19962471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries.
    Lee CW; Suh J; Lee SW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 May; 69(6):821-5. PubMed ID: 17191211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference in neointimal appearance between early and late restenosis after sirolimus-eluting stent implantation assessed by optical coherence tomography.
    Ino Y; Kubo T; Kitabata H; Ishibashi K; Tanimoto T; Matsuo Y; Shimamura K; Shiono Y; Orii M; Komukai K; Yamano T; Yamaguchi T; Hirata K; Tanaka A; Mizukoshi M; Imanishi T; Akasaka T
    Coron Artery Dis; 2013 Mar; 24(2):95-101. PubMed ID: 23363984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients.
    Du R; Zhang RY; Zhu ZB; Zhang Q; Hu J; Yang ZK; Yan ZJ; Lv AK; Ding FH; Zhang JS; Shen WF
    Coron Artery Dis; 2010 May; 21(3):175-81. PubMed ID: 20305549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases.
    Lemos PA; Saia F; Ligthart JM; Arampatzis CA; Sianos G; Tanabe K; Hoye A; Degertekin M; Daemen J; McFadden E; Hofma S; Smits PC; de Feyter P; van der Giessen WJ; van Domburg RT; Serruys PW
    Circulation; 2003 Jul; 108(3):257-60. PubMed ID: 12860901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neointimal coverage of sirolimus-eluting stents 6 months and 12 months after implantation: evaluation by optical coherence tomography.
    Yao ZH; Matsubara T; Inada T; Suzuki Y; Suzuki T
    Chin Med J (Engl); 2008 Mar; 121(6):503-7. PubMed ID: 18364133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravascular ultrasound, angioscopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimus-eluting stent implantation: insights into potential "thromborestenosis" phenomenon.
    Oikawa Y; Yajima J; Costa MA; Matsuno S; Akabane M; Funada R; Inaba T; Nakagawa Y; Nakamura M; Nagashima K; Kirigaya H; Ogasawara K; Sawada H; Aizawa T
    EuroIntervention; 2010 Aug; 6(3):380-7. PubMed ID: 20884418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel neointimal formation over sirolimus-eluting stents identified by coronary angioscopy and optical coherence tomography.
    Murakami D; Takano M; Yamamoto M; Inami S; Ohba T; Seino Y; Mizuno K
    J Cardiol; 2009 Apr; 53(2):311-3. PubMed ID: 19304139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis.
    Habara S; Mitsudo K; Goto T; Kadota K; Fujii S; Yamamoto H; Kato H; Takenaka S; Fuku Y; Hosogi S; Hirono A; Yamamoto K; Tanaka H; Hasegawa D; Nakamura Y; Tasaka H; Otsuru S; Okamoto Y; Yamada C; Miyamoto M; Inoue K
    Heart; 2008 Sep; 94(9):1162-5. PubMed ID: 18032460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Two-year clinical follow-up in 200 patients receiving sirolimus-eluting stents in lesions at a high risk of restenosis].
    de la Torre-Hernández JM; Sainz-Laso F; Llano-Cardenal M; Ruiz-Lera M; Fernández-Friera L; Burgos V; Zueco J; Figueroa A; Colman T
    Rev Esp Cardiol; 2006 Mar; 59(3):225-31. PubMed ID: 16712746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
    Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
    Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.